ENHERTU is also being studied in several ongoing breast cancer trials, including the DESTINY-Breast05 phase 3 trial, which is evaluating ENHERTU in the high-risk adjuvant early HER2 positive setting.

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive metastatic breast cancer.

Trastuzumab deruxtecan approved to treat adults with HER2-positive cancer that’s spread or can’t be removed by surgery.

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim analysis and potential regulatory approvals.

ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY ...

Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In 2022, the drug became the first therapy approved for HER2-low breast ...

Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings ...

TOKYO & BASKING RIDGE, N.J., January 27, 2025--ENHERTU Approved in the U.S. as First HER2 Directed Therapy for HER2 Low or HER2 Ultralow mBC Following Disease Progression After Endocrine Therapy ...

TOKYO& BASKING RIDGE, N.J.---- Daiichi Sankyo and AstraZeneca have been awarded The Galien Foundation 2024 Prix Galien USA Award for Best Biotechnology Product for ENHERTU ®. ENHERTU is a ...

Combined Enhertu sales for AstraZeneca and Daiichi Sankyo reached $893 million in the second quarter, or 1.6% sequential growth from the first quarter.

The approval was based on data from a phase 3 trial that included adults with unresectable or metastatic HER2-low breast cancer who had previous lines of chemotherapy.

The data put Enhertu on track to become the first HER-targeted therapy for a new breast cancer category called HER2-low.